Target intelligence / Profile preview

CNTNAP2 antisense RNA 1 (CNTNAP2-AS1)

Target
CNTNAP2-AS1
Molecular classification
Long non-coding RNA, Antisense RNA
01

Overview

CNTNAP2 antisense RNA 1 (CNTNAP2-AS1) is a long non-coding RNA gene situated at chromosome 7 (location 7q35) and transcribed antisense to CNTNAP2, a neuronal cell adhesion molecule implicated in epilepsy, autism spectrum disorder, intellectual disability, and other neurological disorders. As a non-coding RNA, CNTNAP2-AS1 does not encode a protein but likely functions in the regulation of gene expression through epigenetic and post-transcriptional mechanisms, particularly influencing the expression of CNTNAP2. There is evidence that antisense RNAs, including those at autism susceptibility loci, have region- and tissue-specific functions in the brain, supporting a possible role in neurodevelopmental processes. However, the detailed molecular mechanisms and physiological roles of CNTNAP2-AS1 are as yet incompletely characterized, and it is not considered a direct therapeutic target by current definitions.

Other names
CNTNAP2-AS1
02

Mechanism of action

Not established for drug action. Antisense oligonucleotide therapeutics theoretically could target lncRNAs for degradation or functional modulation.

03

Biological functions

Regulation of gene expression (specifically regulating the sense CNTNAP2 mRNA)Epigenetic modulationLikely involved in neural development and cortical function based on brain-specific expression of antisense RNAs
04

Disease associations

Possible involvement in autism spectrum disorder and other neurodevelopmental conditions via regulation of CNTNAP2 expression
05

Safety considerations

No direct or established safety concerns; however, manipulating the expression of lncRNAs such as CNTNAP2-AS1 could have off-target or unanticipated biological effects due to the complex regulation of gene expression in the brain
06

Biomarkers

Not directly established as a clinical biomarker; changes in CNTNAP2-AS1 expression may indirectly serve as a research biomarker for certain neurological conditions

Beyond the preview

Go deeper on CNTNAP2 antisense RNA 1 (CNTNAP2-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CNTNAP2 antisense RNA 1 (CNTNAP2-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call